CYSTADANE *
Manufacturer Details
RARE DISEASE THERAPEUTICS INC.
Rare Disease Therapeutics Inc
Compositions:
Betaine Anhydrous 1g/1.7ml white granular powder in 180g bottles,
Strength
|
Rate
|
Packing Style
|
1g/1.7ml pow.
|
0.00
|
in 180 g bottles
|
List of Related Indications:
List Of Drugs:
- Betaine Anhydrous - @ -Endrocrine/ Metabolic Disorders
Indication Type Description:
Pharmacology/ Pharmacokinetics
Indication:
Homocystinuria
Homocystinurias (463)
Homocystinurias are three biochemically and clinically distinct disorders each characterized
by increased concentration of sulfur-containg amino acid , homocysteine , in blood and urine.
The most common form results from markedly reduced catalying a key step in transsulfuration
pathway by which methionine is converted to cysteine.
Depending on the underlying disorder , some patients with each of the homocysteinuria show chemical
and in some instances clinical improvement following adminstration of specific improvements
following administreration of specific vitamin supplements (pyrodoxine, folate, or cobalamin )
Adverse Reaction:
Adverse reactions-
Nausea , GI distress, diarrhea, aspirated the powder, caused odor,
questionalble pscychological changes, unspecified problem
Contra-Indications:
Special Precautions
Pregnancy- betaine can cause fetal harm when administered to a pregnant woman or can
affect reproductive capacity. Give to pregnant woman only if clearly needed
Lactation- excrcise caution when administering to a nursing woman
Children- Majority of case studies of homocytinuria patients treated with betaine have been
pediatric patients. Patients have been treated successfully without adverse efects within the
first months or years of life with dosage greater than or equal to 6g/day with resultant
biochemical and clinical improvement
Dosages/ Overdosage Etc:
Indication-
Homocystinuria
Dosage-
The usual dosage in adults and pediatric patients is 6g/day administred orally in divided doses
of 3g twice daily.
Dosages upto 20g/day have been necessar to control homocysteine levels in some patients
In pediatric patric patients less than 3 years of age dosage may be started at 100mg/kg/day
and then increased weekly by 1oomg/kg/day increments.
Dosage in all patients can be gradually increased until plasma homocysteine levels is undetectable
or present only in small amounts.
Measure prescribed amount with the measuring scoop provided ( one level 1.7ml scoop is equal
to 1g betaine anhydrous powder ) and then dissolve in 120ml to 180ml ( 4 to 6 0z ) of water for
immediate ingestion
Patient Information:
1. Shake bottle before removing cap
2. Measure with scoop provided.
3.One level scoop ( 1.7ml ) is equivalent to 1g betaine anhydrous powder. Measure the number
of scoops your physician has precscribed
4. Mix with 120 to 180 ( 4 to 60 oz ) of water until completely dissolved then drink immediately
5. Always replace the cap tightly after using . Protect from moisture. Do not use if powder does not
completely dissolve or gives a colored solution.
Pharmacology/ Pharmacokinetics:
Pharmacology-
Betaine acts as methyl group donor in the remethylation of homocysteine to methionine in patients
with momocystinuria. As a result toxic blood levels of momocysteine are reduced in these patients,
usually 20% to 30% or less of pre-treatment levels.
Elevated homocysteine blood levels are associated with clinical problems such as cardiovascular
thrombosis, osteoporosis, skelatal abnormalites and optic lens dislocation
Pregnancy and lactation:
Pregnancy-
Betaine can cause fetal harm when administered to a pregnant woman or can
affect reproductive capacity. Give to pregnant woman only if clearly needed
Lactation-
Exercise caution when administering to a nursing woman
Children-
Majority of case studies of homocystinuria patients treated with betaine have been
pediatric patients. Patients have been treated successfully without adverse efects within the
first months or years of life with dosage greater than or equal to 6g/day with resultant
biochemical and clinical improvement